Clinical Trial Update: A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administration of NE-58095 Tablets [Phase 2, Phase 3]

View source ↗

Summary

Phase II/III double-blind trial of NE-58095 tablets in involutional osteoporosis completed. Trial results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• NE-58095

Snippet

Sponsor: Takeda | Conditions: Involutional Osteoporosis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2017-02-23